GSK Shares Slip After FDA Flags Eye Safety Risks in Blood Cancer Drug Review

GSK (NYSE: GSK) is facing some tough questions from the FDA's review team regarding its latest blood cancer treatment. Behind the scenes, FDA staff have flagged safety issues tied to the drug, particularly when it's paired with other therapies.

The sticking point? The drug appears to carry a risk of causing eye damage in patients who receive it alongside other treatments. That's a serious red flag for a medication aimed at cancer, where balancing efficacy and side effects is already a complex juggle.

This development throws a wrench into GSK's timeline for approvals and raises the bar for additional safety data. The FDA reviewers didn't mince words about the potential ocular complications, which could complicate the drug's rollout if not addressed robustly.

Seen through the lens of stock moves, GSK's shares have come under some pressure since the FDA flagged the concerns. It's a reminder that even big pharma giants aren't immune to bumps in regulatory roads-especially when dealing with cancers, where safety margins can get razor-thin.

As the FDA process continues, eyes are likely to stay fixed on any updates about how GSK plans to manage these safety risks. Whether this issue slows down the blood cancer drug's launch, or spurs tweaks to the regimen, remains to be seen.